Primary efficacy and safety analysis of a global phase II study of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): The TIDAL study Meeting Abstract
| Authors: | Phillips, T.; Jurczak, W.; Ribrag, V.; Linton, K.; Collin, G. P.; Lopéz-Jimenéz, J.; Reddy, N.; Mengarelli, A.; Musuraca, G.; Sheehy, O.; Xu, W.; Azoulay, M.; Ghalie, R. G.; Zinzani, P. L.; Zelenetz, A. D. |
| Abstract Title: | Primary efficacy and safety analysis of a global phase II study of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): The TIDAL study |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | clinical trial; inhibitor; phase ii; follicular lymphoma; ibcl; zandelisib; tidal; pi3k. |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S387 |
| End Page: | S388 |
| Language: | English |
| ACCESSION: | WOS:000897948100434 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01555-5 |
| Notes: | Meeting Abstract: IBCL-271 -- Source: Wos |
